Bottom line
EUGCX vs BBEU: the short answer
EUGCX (Morgan Stanley Europe Opportunity Fund Inc.) and BBEU (JPMorgan BetaBuilders Europe ETF) are both mutual funds.
BBEU is cheaper at 0.09% vs 1.9% — a difference of $181 a year per $10,000 invested.
Over five years, BBEU returned +10.6% a year vs −0.6% for EUGCX.
Updated Nov 19, 2026
EUGCX vs BBEU side by side
| EUGCX | BBEU | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Morgan Stanley | J.P. Morgan |
| Category | Single Country / Region | Single Country / Region |
| Expense ratio | 1.9% | 0.09% |
| Annual cost per $10k | $190 | $9 |
| 10-yr cost on $10k (prospectus) | $2,717 | $115 |
| Max front load | 0% | None |
| 12b-1 fee | 0.75% | — |
| 1-yr return | +11.0% | +35.7% |
| 5-yr return (annualized) | −0.6% | +10.6% |
| 10-yr return (annualized) | +6.8% | — |
| Best quarter | — | +21.1% |
| Worst quarter | — | −24.9% |
| Net assets (fund) | — | $9.4B |
| Number of holdings | — | 362 |
| Portfolio turnover | 17% | 5% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
EUGCX and BBEU share none of their top holdings.
EUGCX top 10
BBEU top 10
- ASML Holding NV — 4.58%
- HSBC Holdings plc — 2.62%
- Roche Holding AG — 2.16%
- Novartis AG — 2.14%
- AstraZeneca plc — 1.89%
- Shell plc — 1.83%
- Nestle SA — 1.78%
- JPMorgan Securities Lending Money Market Fund — 1.78%
- Siemens AG — 1.68%
- Banco Santander SA — 1.46%
FAQ
What is the difference between EUGCX and BBEU?
EUGCX (Morgan Stanley Europe Opportunity Fund Inc.) and BBEU (JPMorgan BetaBuilders Europe ETF) are both mutual funds. BBEU is cheaper at 0.09% vs 1.9% — a difference of $181 a year per $10,000 invested.
Which is cheaper, EUGCX or BBEU?
BBEU has the lower expense ratio (0.09%).
Should I own both EUGCX and BBEU?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.